Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute of Hospital La Fe, Fernando Abril Martorell 106, 46026, Valencia, Spain.
Angiology and Vascular Surgery Service, La Fe University and Polytechnic Hospital, Fernando Abril Martorell 106, 46026, Valencia, Spain.
Curr Urol Rep. 2020 Mar 13;21(2):11. doi: 10.1007/s11934-020-0962-9.
Renal cell carcinoma (RCC) is the third most common urologic malignancy. First symptoms are usually unspecific and belated causing the stages to be high when diagnosed. As compensation, incidental detection of RCC by abdominal imaging techniques for other medical purposes is a reality that favours a decrease in the stage of new diagnosed tumours. Therefore, identifying novel predictive biomarkers for diagnosis, progression and prognosis of RCC is fundamental.
To date, several studies have demonstrated that microRNAs (miRNAs) play a role in the particular scenario of urologic tumors, and alterations at miRNA level are involved in the initiation, progression and metastases formation of renal cancer. In the present review, we have summarized the up‑to‑date preliminary clinical works on the role of urinary miRNA profiling in RCC, including an evaluation of its value as a potential biomarker for diagnosis, prognosis and follow up of RCC patients.
肾细胞癌（RCC）是第三大常见的泌尿系统恶性肿瘤。首发症状通常不具有特异性且较晚出现，导致诊断时分期较高。为了弥补这一缺陷，在因其他医疗目的进行腹部影像学检查时意外发现 RCC 的情况较为常见，这有利于降低新诊断肿瘤的分期。因此，寻找用于 RCC 诊断、进展和预后的新型预测性生物标志物至关重要。
迄今为止，多项研究表明 microRNAs（miRNAs）在泌尿系统肿瘤的特定情况下发挥作用，miRNA 水平的改变与肾癌的发生、进展和转移形成有关。在本综述中，我们总结了关于尿 miRNA 谱在 RCC 中的作用的最新临床前期研究工作，包括评估其作为 RCC 患者潜在诊断、预后和随访生物标志物的价值。
